Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 12Recruiting 6Unknown 2Terminated 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 47Thoracic 2Genitourinary 2Sarcoma 1Other hematologic neoplasm 1NET 1Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 7Pheochromocytoma 6Thyroid Carcinoma, Anaplastic 5Pituitary Neoplasms 5Paraganglioma 5Insulinoma 5Somatostatinoma 4Vipoma 3Serotonin Syndrome 3Lung Neoplasms 3Glucagonoma 3Gastro-enteropancreatic neuroendocrine tumor 3Gastrinoma 3Carcinoma, Neuroendocrine 3Carcinoma, Merkel Cell 3Carcinoma, Medullary 3Carcinoma, Islet Cell 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Unknown Primary 2Neoplasms 2Multiple Endocrine Neoplasia Type 1 2Head and Neck Neoplasms 2Growth Hormone-Secreting Pituitary Adenoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Liver Neoplasms × Endocrine × Clear all
NCT01864070 2014-07-22

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

M.D. Anderson Cancer Center

Phase 1 Withdrawn
EndocrineGastrointestinalNET

Liver Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡